Pure Global AI
NCT06273462Not yet recruiting

Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

Randomized Placebo-Controlled Trial of Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
Navy Medical Center San DiegoPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Pain
Drug/Device/Intervention
Palmitoylethanolamide 600mg twice a day
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Navy Medical Center San Diego
Location
San Diego, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2024
End date
May 30, 2025
Enrollment
80 participants
Primary outcome

Pain Level

Summary

The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide
 (PEA) is effective in reducing the pain in patients with chronic inflammatory pain
 conditions. The main question the trial aims to answer is if PEA works better at treating a
 patients pain and improving their function better than a placebo.
 
 Participants will be divided into two equal groups and asked to take either PEA or a placebo
 for 8 weeks.

ICD-10 classifications
Other chronic painChronic intractable painPain, not elsewhere classifiedPain, unspecifiedPain associated with micturition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06273462
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06273462 through Pure Global AI's free database. This Phase 2 trial is sponsored by Navy Medical Center San Diego and is currently Not yet recruiting. The study focuses on Chronic Pain. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.